Reports Q4 revenue $18.8M, consensus $18.95M.”We are extremely proud of our achievements in 2023 and our team’s remarkable resilience, focus, and determination throughout a challenging LCD process in the back half of the year that ultimately resulted in the LCDs being withdrawn. We added highly experienced medtech growth leadership to our team, restructured our commercial organization for both increased efficiency and effectiveness, and meaningfully reduced our cash burn during a transient period of uncertainty, which I believe will lead to predictable long-term results as we enter our next exciting phase of transformative growth,” said Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences. “We believe we have multiple catalysts to be excited about in 2024. We plan to expand the library of clinical data demonstrating the differentiated safety and efficacy profiles of our interventional glaucoma and dry eye technologies, make significant progress towards meaningful reimbursement for TearCare, and based on the productive start to the year we expect to return to double-digit revenue growth in the second half of 2024 with our elevated commercial infrastructure and strategy,” continued Mr. Badawi.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SGHT:
- Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
- SGHT Earnings this Week: How Will it Perform?
- Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
- Sight Sciences launches Ergo-Series of OMNI Surgical System in Europe
- Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting